$0.88 0.9%
ADAP Stock Price vs. AI Score
Data gathered: October 14

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.


Adaptimmune Therapeutics
Price $0.88
Target Price Sign up
Volume 1,780,000
Market Cap $223M
Year Range $0.83 - $1.75
Dividend Yield 0%
Analyst Rating 63% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '24128M19M109M70M69M0.240
Q1 '245.7M20M-14M-49M-49M-0.180
Q4 '23740,00019M-18M-48M-51M-0.240
Q3 '237.3M16M-8.8M-46M-46M-0.200
Q2 '235.1M20M-15M-21M-65M-0.230

Insider Transactions View All

Piccina Cintia filed to sell 38,293 shares at $0.9.
June 18 '24
Bertrand William C JR filed to sell 7,785 shares at $0.7.
January 17 '24
Lunger John filed to sell 7,785 shares at $0.7.
January 17 '24
Norry Elliot filed to sell 7,785 shares at $0.7.
January 17 '24
Bertrand William C JR filed to sell 20,201 shares at $0.7.
January 17 '24

What is the Market Cap of Adaptimmune Therapeutics?

The Market Cap of Adaptimmune Therapeutics is $223M.

What is the current stock price of Adaptimmune Therapeutics?

Currently, the price of one share of Adaptimmune Therapeutics stock is $0.88.

How can I analyze the ADAP stock price chart for investment decisions?

The ADAP stock price chart above provides a comprehensive visual representation of Adaptimmune Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adaptimmune Therapeutics shares. Our platform offers an up-to-date ADAP stock price chart, along with technical data analysis and alternative data insights.

Does ADAP offer dividends to its shareholders?

As of our latest update, Adaptimmune Therapeutics (ADAP) does not offer dividends to its shareholders. Investors interested in Adaptimmune Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Adaptimmune Therapeutics?

Some of the similar stocks of Adaptimmune Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.